[Clinical assessment of potential fields of application of recombinant factor VIIa in internal and pediatric diseases. Recommendations of an expert group].
Recombinant factor VIIa (rFVIIa) is increasingly used outside the labeled indications for treatment of life-threatening bleeding episodes after failure of the respective standard therapy. An interdisciplinary group of experts summarizes the state of knowledge of the use of rFVIIa in gastroenterology and hepatology, thrombocytopenia and -pathia, coagulation factor deficiencies, von Willebrand's disease, periinterventional bleeding without specific bleeding diathesis, drug-induced bleeding, disseminated intravascular coagulation, and neonatology. The most commonly used dose is 90 microg/kg body weight rFVIIa as bolus, if necessary followed by additional injections at intervals of 2-3 h. In factor VII deficiency lower dosages of 15-30 microg/kg body weight of rFVIIa are given every 4-6 h, whereas higher doses of 150-200 microg/kg body weight are used in neonates.
Dempfle
Carl-Erik
CE
Hämostaseologie, Klinikum Mannheim gGmbH, Mannheim.
Gulba
Dietrich
D
Kirchmaier
Carl M
CM
Klamroth
Robert
R
Korte
Wolfgang
W
Lorenz
Reinhard
R
Peck-Radosavljevic
Markus
M
Veldman
Alex
A
Zotz
Rainer B
RB
D000328:Adult; D002648:Child; D017277:Drug Approval; D019317:Evidence-Based Medicine; D005168:Factor VII Deficiency / Q000097:blood / Q000188:drug therapy*; D015942:Factor VIIa / Q000008:administration & dosage*; D005858:Germany; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage
D011994:Recombinant Proteins; D015942:Factor VIIa